Intercept(Biotechnology) Overview

  • Founded
  • 2002
Founded
  • Status
  • Public
  • Employees
  • 583
Employees
  • Stock Symbol
  • ICPT
Stock Symbol
  • Share Price
  • $28.94
  • (As of Thursday Closing)

Intercept(Biotechnology) General Information

Description

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 10 Hudson Yards
  • 37th Floor
  • New York, NY 10001
  • United States
+1 (646) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Intercept(Biotechnology) Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$28.94 $28.76 $27.76 - $125.00 $954M 33M 758K -$10.32

Intercept(Biotechnology) Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 1,582,995 3,875,512 2,867,014 1,325,697
Revenue 283,351 252,002 179,804 130,956
EBITDA (288,814) (299,874) (274,137) (326,495)
Net Income (339,255) (344,681) (309,242) (360,367)
Total Assets 637,494 754,886 509,167 484,347
Total Debt 558,858 538,534 371,250 355,677
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Intercept(Biotechnology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Intercept(Biotechnology)‘s full profile, request access.

Request a free trial

Intercept(Biotechnology) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Intercept(Biotechnology)‘s full profile, request access.

Request a free trial

Intercept(Biotechnology) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chr
Drug Discovery
New York, NY
583 As of 2019
00000
000000 - 000 00000

0000000

liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000 000000000
Copenhagen North, Denmark
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris n
0000 000000000
San Diego, CA
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intercept(Biotechnology) Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Galecto Formerly VC-backed Copenhagen North, Denmark 00 00000 00000000 00000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000 - 000 00000
00000000 Venture Capital-Backed San Francisco, CA 0 0000 000000000 - 0000
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 00000000000 00000
0000 000000000000 Venture Capital-Backed London, United Kingdom 00 000.00 00000000000 000.00
You’re viewing 5 of 51 competitors. Get the full list »

Intercept(Biotechnology) Executive Team (15)

Name Title Board Seat Contact Info
Mark Pruzanski MD Chief Executive Officer & Founder
Lisa Bright President
Michael Donnelly MD President
Sandip Kapadia Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Jerome Durso Chief Operating Officer, Operations
You’re viewing 5 of 15 executive team members. Get the full list »

Intercept(Biotechnology) Board Members (14)

Name Representing Role Since
Daniel Bradbury Self Board Member 000 0000
Daniel Welch Self Board Member 000 0000
Gino Santini Self Board Member 000 0000
Glenn Sblendorio Self Board Member 000 0000
Keith Gottesdiener MD Intercept(Biotechnology) Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Intercept(Biotechnology) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intercept(Biotechnology) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Intercept(Biotechnology)‘s full profile, request access.

Request a free trial